Satellos Bioscience Inc. (MSCL.TO)

CAD 0.89

(-4.3%)

Operating Expenses Summary of Satellos Bioscience Inc.

  • Satellos Bioscience Inc.'s latest annual operating expenses in 2023 was 6.64 Million CAD , up 83.47% from previous year.
  • Satellos Bioscience Inc.'s latest quarterly operating expenses in 2024 Q1 was 8.25 Million CAD , up 32.12% from previous quarter.
  • Satellos Bioscience Inc. reported a annual operating expenses of 8.42 Million CAD in annual operating expenses 2022, up 79.27% from previous year.
  • Satellos Bioscience Inc. reported a annual operating expenses of 4.7 Million CAD in annual operating expenses 2021, up 229.45% from previous year.
  • Satellos Bioscience Inc. reported a quarterly operating expenses of 6.67 Million CAD for 2024 Q2, down -78.12% from previous quarter.
  • Satellos Bioscience Inc. reported a quarterly operating expenses of 4.48 Million CAD for 2023 Q3, up 47.72% from previous quarter.

Annual Operating Expenses Chart of Satellos Bioscience Inc. (2023 - 2019)

Historical Annual Operating Expenses of Satellos Bioscience Inc. (2023 - 2019)

Year Operating Expenses Operating Expenses Growth
2023 6.64 Million CAD 83.47%
2022 8.42 Million CAD 79.27%
2021 4.7 Million CAD 229.45%
2020 1.42 Million CAD 91.86%
2019 743.79 Thousand CAD 0.0%

Peer Operating Expenses Comparison of Satellos Bioscience Inc.

Name Operating Expenses Operating Expenses Difference
Appili Therapeutics Inc. 8.83 Million CAD 24.793%
Eupraxia Pharmaceuticals Inc. 37.92 Million CAD 82.475%
Helix BioPharma Corp. 9.35 Million CAD 28.973%
Microbix Biosystems Inc. 10.21 Million CAD 34.956%
Medicenna Therapeutics Corp. 19.66 Million CAD 66.2%
Oncolytics Biotech Inc. 33.79 Million CAD 80.332%
Sernova Corp. 41.13 Million CAD 83.842%